GU Cancers 2022 | Unmet needs in the treatment of renal cell carcinoma

Yousef Zakharia, MD, University of Iowa, Iowa City, IA, outlines the areas of unmet needs in renal cell carcinoma (RCC). Despite the success observed with immunotherapy (IO) and tyrosine kinase inhibitors (TKIs) in treating kidney cancer, there are a number of patients who do not respond well and do not respond over prolonged periods of time. Unmet needs lie in the refractory setting where research into additional targets is imperative. Additionally, there is data lacking in the field of non-clear cell RCC in regards to IO and TKIs. There is prospective data on IO and TKIs for non-clear cell RCC, however, a lot of this data has been extrapolated from data on patients with clear-cell RCC, despite the differing biologies. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.